The BTK inhibitor ibrutinib (PCI-32765) in combination with rituximab is well tolerated and displays profound activity in high-risk chronic lymphocytic leukemia (CLL) patients

This article has no abstract
Epistemonikos ID: dd31bb14172259852cdc243e97695d1a0ed7dfb0
First added on: Feb 05, 2025